What Adalat Treats: Main Uses and Benefits

Adalat is commonly used to provide symptomatic support across several cardiovascular domains. Its primary application is the long-term management of essential high blood pressure, a condition characterized by symptoms related to systemic imbalance. The stabilization of arterial pressure may play a role in managing these symptoms and supports general well-being during symptomatic phases.

It is also applied across domains where additional symptomatic support is needed for Angina Pectoris, including both effort-associated chest discomfort and the heightened, episodic symptoms of Vasospastic Angina. The key benefit provided may assist with easing the symptom burden related to recurrent episodes, offering symptomatic relief that generally contributes to improved comfort during symptomatic periods.

Furthermore, this medicine is considered relevant for easing symptoms related to peripheral vasospasm, such as those experienced in Raynaud's Phenomenon. This application provides supportive relief for groups of symptoms that become more disruptive during flare-ups and supports general well-being during symptomatic phases. In specific high-risk contexts, such as blood pressure management in severe hypertension during pregnancy (preeclampsia), the drug may be part of symptomatic management applied in scenarios where additional management of discomfort is required.

---

Quick Fact: Symptomatic Support Profile

Symptom Category	Therapeutic Focus
Recurrent Chest Discomfort	Applied in contexts marked by increased discomfort or tension related to Angina Pectoris.
Sustained High Arterial Pressure	Used in areas where short-term symptom management is appropriate for systemic imbalance.
Peripheral Coldness and Pain	Relevant for managing symptoms that interfere with daily comfort due to vasospasm.

Regulatory References

1. NIH MedlinePlus overview

Eligibility for Adalat (Nifedipine) — Official Regulatory Information

Adalat is primarily designated for adult patients (18 years and older) with hypertension or chronic stable angina. Use in children and adolescents is not recommended because safety and efficacy have not been established in this age group.

---

Classification	Population/Condition
ABSOLUTE CONTRAINDICATION	Cardiogenic shock, Unstable Angina Pectoris, Myocardial Infarction (within one month), Clinically Significant Aortic Stenosis, or Known Hypersensitivity to nifedipine [Source: 1.1, 1.6].
CONTRAINDICATION	Concomitant use with Rifampicin; use during pregnancy (with rare exceptions for severe, unresponsive maternal hypertension); and use during lactation [Source: 1.4, 2.7].
RESTRICTED USE	Hepatic impairment requires careful monitoring, and a dose reduction may be necessary in severe cases. Patients with poor cardiac reserve (potential heart failure) or severe hypotension must be monitored closely [Source: 1.1, 1.4].
FORMULATION RESTRICTION	Prolonged-release forms are contraindicated in patients with gastrointestinal obstruction or Kock pouch [Source: 1.4]. Immediate-release capsules are generally avoided in older adults due to increased risk of adverse events [Source: 1.3].

---

Regulatory documentation strictly classifies patient eligibility based on pre-existing conditions and physiological status. This framework establishes absolute prohibitions for acute cardiac instability and specific concurrent therapies, while mandating cautious or monitored use for groups with compromised organ function or specialized gastrointestinal status.

Interactions with other medicines and products

Adalat (Nifedipine) has a documented interaction profile primarily based on the Cytochrome P450 3A4 (CYP3A4) enzyme system, which is responsible for its metabolism. The presence of other substances that interfere with this enzyme can significantly alter Nifedipine's systemic exposure, as stated in regulatory prescribing information.

Co-administration with Rifampicin (Rifampin) is formally contraindicated by government regulators, as Rifampicin strongly induces CYP3A4, causing a severe reduction in Nifedipine plasma concentrations and a loss of its therapeutic effect.

Exposure-Altering Interactions

Substance Category	Interaction Outcome (Official Description)
CYP3A4 Inhibitors (e.g., Azole Antimycotics, Protease Inhibitors)	Increase Nifedipine plasma concentration and exposure (AUC).
CYP3A4 Inducers (e.g., Phenytoin, Carbamazepine)	Decrease Nifedipine systemic exposure and potentially reduce efficacy.

Pharmacodynamic and Food Interactions

The co-administration of Nifedipine with other antihypertensives is documented to result in an additive blood pressure lowering effect. Nifedipine may also increase the plasma concentration of co-administered drugs like Digoxin and the immunosuppressant Tacrolimus.

Regarding food and supplements, regulatory authorities have specifically documented that the consumption of Grapefruit or Grapefruit Juice inhibits CYP3A4-mediated metabolism, causing a substantial increase in Nifedipine exposure. Conversely, the herbal product St. John’s Wort decreases exposure by inducing the same enzyme.

Calcium Channel Blockade: The Core Mechanism

Adalat (nifedipine) functions as a dihydropyridine calcium channel blocker (CCB), selectively targeting the L-type voltage-gated calcium channels in the smooth muscle cells of peripheral and coronary arteries. By binding to these channels, the drug inhibits the transmembrane influx of extracellular calcium ions (Ca^2+), which are key signaling molecules for initiating muscle contraction. This action directly suppresses the signal transduction sequence that requires calcium to trigger the tightening of arterial walls.

---

Vascular Modulation and Hemodynamic Effects

This core mechanism results in the relaxation of the smooth muscles in both peripheral and coronary arteries. The change in tension leads to vasodilation, causing a widening of the arterial lumen and facilitating a decrease in the resistance exerted by the blood vessels on circulating blood flow. The resultant decrease in overall systemic vascular resistance lowers the cardiac afterload, which is the pressure opposing ventricular ejection. Concurrently, coronary vasodilation increases the diameter of the coronary vessels.

How Adalat (Nifedipine) is Used

The administration of Nifedipine is guided by specific instructions to ensure the proper delivery of the medication. The approved route of administration for all marketed forms of Adalat, including immediate-release capsules and extended-release tablets, is oral.

Extended-release formulations are typically prescribed for once-daily use, requiring the patient to take the tablet at the same time each day for consistent systemic exposure. These extended-release tablets must be swallowed whole and are not to be crushed, chewed, or divided. This instruction is essential to maintain the integrity of the controlled-release mechanism built into the medication.

Official Dosing and Administration Schedules

The dosage for Adalat is subject to gradual adjustment, or titration, which is typically performed over a 7- to 14-day period to reach the maintenance level. Starting doses for the extended-release forms usually begin at 30 mg or 60 mg, with maintenance ranges extending up to 90 mg (or 120 mg in some global regions).

Formulation Type	Typical Frequency	Maximum Daily Dose (Range)
Extended-Release (ER) Tablet	Once Daily	90 mg – 120 mg
Immediate-Release (IR) Capsule	Three to Four Times Daily	180 mg (divided doses)

Established guidance emphasizes specific contextual constraints for proper use. Patients taking Adalat are explicitly instructed to avoid consumption of grapefruit or grapefruit juice. Furthermore, if a dose is missed, guidance advises the patient to skip the missed dose entirely and proceed with the next scheduled dose; doubling the dose is not part of the official procedure. Population-specific instructions note that patients with impaired liver function may require a dose reduction and careful monitoring.

Research Evidence Overview: Essential High Blood Pressure

Research has extensively studied Nifedipine in adults with essential hypertension, characterized by systemic or functional imbalance. Large-scale randomized controlled trials (RCTs) and systematic reviews research examined changes in systolic and diastolic blood pressure (BP). Studies consistently reported measurements indicating shifts in BP over defined time intervals. Findings from large-scale outcome trials described patterns related to the tracking of rates for major cardiovascular events in observed populations over time.

Research Evidence Overview: Angina Pectoris

The evidence base for chronic stable angina and vasospastic angina includes RCTs focused on conditions characterized by fluctuating or episodic manifestations. These studies were evaluated in adult populations, examining outcomes related to physical discomfort, and tracking the frequency and perceived severity of episodes of chest discomfort. For vasospastic angina, trials showed patterns related to the frequency and intensity of vasospastic attacks, particularly in research exploring short-term symptom changes.

Evidence in Specific Patient Groups and Long-Term Data

Research has been studied for Nifedipine in specific adult populations, including those with comorbidities like diabetes. These findings describe how the substance was observed in these subgroups within the large-scale hypertension trials. For severe hypertension during pregnancy (preeclampsia), focused Clinical Trials researched examined the parameters of acute blood pressure change.

Long-term research efforts have examined major clinical outcomes in hypertension studies with follow-up periods extending over several years. However, a key research limitation frame is that long-term effects are not fully established for certain specific symptomatic outcomes, such as those related to Raynaud's phenomenon. Furthermore, research data for the pediatric population remain insufficient as comprehensive studies have not been performed.

Common questions about Adalat (FAQ)

Q: What are the benefits of taking an extended-release (ER) tablet versus an immediate-release (IR) capsule?

Official product information indicates that the extended-release (ER) tablets are specially designed to release the active ingredient at a steady rate over approximately 24 hours. This controlled mechanism typically allows for once-daily dosing, which is intended to help maintain consistent drug levels in the body. In contrast, immediate-release capsules are often administered multiple times throughout the day.

Q: What happens if I forget a dose of Adalat?

The official regulatory guidance advises that if a dose is missed, it should be skipped entirely, and the person should proceed with the next regularly scheduled dose. Regulatory guidance states that the dose should not be doubled to compensate for a missed dose, as this action may increase the risk of excessive lowering of blood pressure (hypotension).

Q: What should I do if I think I've taken too much Adalat?

Official information warns that taking more than the prescribed amount (overdosage) can cause a serious and excessive drop in blood pressure (severe hypotension). In cases of suspected overdose, official information recommends seeking immediate medical attention. Severe hypotension or fluid imbalances have been reported.

Q: What is the half-life of Adalat (Nifedipine)?

The elimination half-life of a medication refers to the time it takes for half the drug to be cleared from the body. Regulatory documents show that the half-life for the immediate-release capsules is approximately two hours. For the extended-release tablets, the elimination half-life is longer, reported to be approximately seven hours.

Q: How long does it take for Adalat to start lowering my blood pressure?

Regulatory information for the immediate-release capsule notes that the drug is absorbed quickly after oral administration, with peak blood levels occurring around 30 minutes. This absorption begins the process of vasodilation (artery widening), which is the mechanism associated with changes in blood pressure readings.

Q: How should I dispose of unused or expired Adalat?

If a medicine take-back program is not available, regulatory guidance suggests that the medicine should not be flushed or thrown into household waste unless specifically instructed. Instead, official methods recommend mixing the medication with an undesirable substance, such as coffee grounds or dirt, sealing it in a plastic bag, and then discarding it with household trash. This disposal method is officially recommended for maintaining household safety.

Q: Is it safe to drink alcohol while taking Adalat?

Official information indicates that alcohol consumption may contribute to the blood pressure lowering effects of Nifedipine. This interaction can increase the risk of experiencing adverse effects such as dizziness, lightheadedness, or feeling faint. Individuals with concerns about alcohol consumption while taking this medication are encouraged to consult their healthcare provider.

How to Store and Dispose of Adalat (Nifedipine)

Adalat tablets must be stored at Controlled Room Temperature, which is strictly maintained between 20 C and 25 C (68 F and 77 F). The medication must be protected from both light and moisture to maintain its required stability.

Storage Requirements

Condition	Requirement
Temperature	Controlled Room Temperature (20 C – 25 C)
Protection	Protect from light and moisture
Packaging	Store in the original container
Child Safety	Keep out of the sight and reach of children

Disposal Instructions

Disposal of unused or expired Adalat must be performed according to local regulatory requirements for pharmaceutical waste. Medicines must not be thrown away via wastewater or household waste.